Casdin Capital as of Sept. 30, 2017
Portfolio Holdings for Casdin Capital
Casdin Capital holds 26 positions in its portfolio as reported in the September 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Loxo Oncology | 9.4 | $33M | 360k | 92.12 | |
| Myokardia | 6.8 | $24M | 560k | 42.85 | |
| Alnylam Pharmaceuticals (ALNY) | 6.6 | $24M | 200k | 117.49 | |
| Sangamo Biosciences (SGMO) | 5.9 | $21M | 1.4M | 15.00 | |
| Blueprint Medicines (BPMC) | 5.9 | $21M | 298k | 69.67 | |
| Bluebird Bio (BLUE) | 5.6 | $20M | 145k | 137.35 | |
| Foundation Medicine | 5.5 | $19M | 480k | 40.20 | |
| Kite Pharma | 5.4 | $19M | 106k | 179.81 | |
| Spark Therapeutics | 5.3 | $19M | 210k | 89.16 | |
| Agios Pharmaceuticals (AGIO) | 4.8 | $17M | 255k | 66.75 | |
| Voyager Therapeutics (VYGR) | 4.7 | $17M | 815k | 20.59 | |
| Sage Therapeutics (SAGE) | 4.2 | $15M | 240k | 62.30 | |
| GenMark Diagnostics | 4.1 | $14M | 1.5M | 9.63 | |
| Evolent Health (EVH) | 4.0 | $14M | 795k | 17.80 | |
| Global Blood Therapeutics In | 3.3 | $12M | 380k | 31.05 | |
| Audentes Therapeutics | 3.2 | $11M | 400k | 28.01 | |
| Clovis Oncology | 3.0 | $11M | 128k | 82.40 | |
| Codexis (CDXS) | 2.8 | $9.8M | 1.5M | 6.65 | |
| Illumina (ILMN) | 2.5 | $8.8M | 44k | 199.20 | |
| Jounce Therapeutics | 1.8 | $6.2M | 400k | 15.58 | |
| Tesaro | 1.4 | $5.0M | 39k | 129.09 | |
| Syros Pharmaceuticals | 1.1 | $3.8M | 256k | 14.72 | |
| Cytomx Therapeutics (CTMX) | 0.9 | $3.2M | 178k | 18.17 | |
| Editas Medicine (EDIT) | 0.9 | $3.2M | 133k | 24.01 | |
| Fate Therapeutics (FATE) | 0.6 | $2.2M | 550k | 3.96 | |
| Ovid Therapeutics (OVID) | 0.5 | $1.8M | 208k | 8.57 |
